Physician Views: How will hematologists and oncologists use Rezurock in chronic GvHD?

Sanofi gained the recently US-approved chronic graft-versus-host-disease (cGvHD) therapy Rezurock this month through its $1.9 billion takeout of Kadmon.

FDA approved Rezurock, a first-in-class Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in July for cGvHD patients 12 and older who have failed at least two prior lines of systemic therapy.

Rezurock has also been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines to manage steroid refractory cGvHD.

To determine the anticipated use cases for Rezurock, we are asking US and Europe-based hematologists and oncologists the following questions…

  • Whether they intend to prescribe Rezurock for cGvHD?
  • In what setting(s) they intend to prescribe Rezurock for cGVHD?
  • In what patient population(s) they intend to prescribe Rezurock for cGvHD?
  • What would be their primary driver behind choosing Rezurock over other approved therapies for cGvHD?

Survey results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here.

To read more Physician Views articles, click here.

Reference Articles